Burning Rock Biotech
BNR
52 hedge funds and large institutions have $55.5M invested in Burning Rock Biotech in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
4% more funds holding
Funds holding: 50 → 52 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.17% less ownership
Funds ownership: 2.82% → 2.65% (-0.17%)
22% less capital invested
Capital invested by funds: $71.2M → $55.5M (-$15.7M)
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$7.76M |
| 2 |
Millennium Management
New York
|
+$4.81M |
| 3 |
Barclays
London,
United Kingdom
|
+$1.78M |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$677K |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$671K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.8M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$4.25M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.67M |
| 4 |
Renaissance Technologies
New York
|
-$1.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.66M |
BNR Hedge Fund Activity: Q3 2022 in Review
52 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q3 2022, worth a combined $55.5M — down 22% from $71.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BNR positions and 9 closed out — a net gain of 2 holders — while 12 added to existing stakes and 19 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $7.76M. The largest seller was Vanguard Group, cutting an estimated $4.8M.
- 52 institutional investors held Burning Rock Biotech (BNR) as of Q3 2022, up from 50 in Q2 2022.
- Funds reported $55.5M of Burning Rock Biotech stock for Q3 2022, down 22% quarter-over-quarter.
- 11 funds opened new Burning Rock Biotech positions in Q3 2022 and 9 closed out, a net change of +2 holders.
- The largest Burning Rock Biotech buyer in Q3 2022 was Kynam Capital Management, an estimated $7.76M added.
- The largest Burning Rock Biotech seller in Q3 2022 was Vanguard Group, an estimated $4.8M sold.
Based on aggregated 13F filings for Q3 2022.